Aiming to cure esophageal cancer without the knife
NCT ID NCT05713838
First seen Aug 07, 2026 · Last updated Aug 07, 2026
Summary
This trial is testing whether a combination of the immunotherapy drug durvalumab, chemotherapy, and radiation can completely eliminate early-stage esophageal cancer, potentially making surgery unnecessary. The study enrolls adults with early-stage (cT1 or cT2N0) esophageal adenocarcinoma who would normally need radical surgery. The goal is to see if this non-surgical approach can achieve a complete response, meaning no cancer remains, and preserve the esophagus.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- durvalumab (an immunotherapy drug) combined with chemotherapy (FLOT or mFOLFOX-6) and radiation therapy
- What this could lead to
- If successful, this approach could allow people with early-stage esophageal cancer to avoid radical surgery, preserving their esophagus while potentially curing the cancer.
- What could go wrong
- This is a small, early-phase trial, so results may not apply broadly. The combination of immunotherapy, chemotherapy, and radiation can cause significant side effects, and not all patients may respond completely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGUS ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Charite Univeristätsmedizin Berlin
Berlin, 13353, Germany
-
Gemeinschaftspraxis für Hämatologie und Onkologie GEHO
Münster, Germany
-
HELIOS Klinikum Bad Saarow
Bad Saarow, Germany
-
Institute of Clinical Cancer Research, University Cancer Center (UCT) Frankfurt Krankenhaus Nordwest
Frankfurt, Germany
-
Kliniken Essen Mitte Klinik für Internistische Onkologie und Hämatologie
Essen, Germany
-
Klinikum Darmstadt GmbH
Darmstadt, 64283, Germany
-
Klinikum Ludwigshafen gGmbH
Ludwigshafen, 67063, Germany
-
Klinikum Mutterhaus Trier
Trier, Germany
-
Klinikum St. Marien Kommunalunternehmen - Anstalt des öffentlichen Rechts der Stadt Amberg
Amberg, Germany
-
Klinikum Wolfsburg
Wolfsburg, Germany
-
Klinikum rechts der Isar der Technischen Universität München
München, Germany
-
Klinikverbund Allgäu gGmbH
Kempten, 87439, Germany
-
Krankenhaus St. Joseph-Stift GmbH
Bremen, 28209, Germany
-
Kreiskliniken Reutlingen GmbH Klinikum am Steinberg Reutlingen Ermstalklinik, Bad Urach
Reutlingen, Germany
-
Leopoldina-Krankenhaus Medizinische Klinik II
Schweinfurt, Germany
-
St. Elisabeth Gruppe GmbH, St. Anna Hospital Herne
Herne, Germany
-
Universitätsklinikum Brandenburg an der Havel Medizinische Hochschule Brandenburg
Brandenburg an der Havel, Germany
-
Universitätsklinikum Halle (Saale) Universitätsklinik und Poliklinik für Innere Medizin I
Halle, Germany
-
Universitätsklinikum Heidelberg, RadioOnkologie & Strahlentherapie
Heidelberg, Germany
-
Universitätsklinikum Schleswig-Holstein
Kiel, 24105, Germany
-
Universitätsmedizin Göttingen
Göttingen, 37075, Germany
-
ÜBAG - Medizinisches Versorgungszentrum Dr. Vehling-Kaiser GmbH
Landshut, 84036, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.